Identification of plasma-based protein markers

Biomarkers provide valuable information of the organic changes underlying cognitive decline, and support the estimation of the severity, progression and course of dementia. Among the most notable biological changes in Alzheimer’s disease is the abnormal accumulation of amyloid-β peptide and tau protein in the brain. Latest research enabled the quantification of these proteins from blood plasma as well, being a promising and more accessible method as compared to the previously used PET and lumbar puncture techniques. In our research we aimed at contributing to the further development of this novel method and facilitating its clinical application by measuring individual amyloid-β and tau levels from blood plasma.

References

Hampel, H., O’Bryant, S. E., Molinuevo, J. L., Zetterberg, H., Masters, C. L., Lista, S., … & Blennow, K. (2018). Blood-based biomarkers for Alzheimer disease: mapping the road to the clinic. Nature Reviews Neurology, 14(11), 639-652.

Schindler, S. E., & Bateman, R. J. (2021). Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia. Nature Aging, 1(1), 26–28.

Zetterberg, H., & Blennow, K. (2020). Blood Biomarkers: Democratizing Alzheimer’s Diagnostics. Neuron, 106(6), 881–883.